Key Drivers
- Strong liquidity
- Massive losses
- High cash burn
AIAI Summary
Vir's pivot to partnered development (Astellas upfront plus a $150M raise) materially derisks funding and reframes the investment from equity‑funded binary bets to milestone‑driven upside, but the decisive opportunity/risk is whether upcoming VIR‑5500 durability/safety data and ECLIPSE registrational results (and timely milestone receipts) validate commercialization — model runway assuming sustained high R&D burn and monitor those readouts/milestone timing as the primary value drivers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Massive losses
- •High cash burn
VIR has a strong balance sheet with ample cash and low leverage but is generating persistent, large operating losses and cash burn that outweigh its tangible-book-level valuation, posing clear short-term and profitability risks.
Price Behavior
Key Price Behavior Insights:
- •Short-term pullback
- •Unconfirmed breakout
- •Elevated volatility
Over the last month the stock rallied ~20% from about $7.56 to $9.10 but sits just below the ~$9.26 short-term average, faces resistance near $10.00, has support in the mid-$7s, and shows elevated volatility after a news-driven gap that raises event risk.
Sharp gap up on 2026-02-24–25 created a discrete, event-driven impulse and higher short-term reversal risk
Sentiment & News
Key News Insights:
- •Astellas deal
- •Promising Phase‑1
- •Equity raise
Vir Biotechnology struck a global oncology pact with Astellas for PSMA T‑cell engager VIR‑5500 alongside positive Phase 1 data, beat 2025 revenue expectations, and executed equity raises that together spurred analyst upgrades and a stock rally.
The Astellas collaboration plus encouraging clinical and financial results de‑risk VIR‑5500's development while the concurrent capital raise funds near‑term programs but may dilute shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings